SAN FRANCISCO
(Map)
-
SAN FRANCISCO, Dec. 4 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN) today announced that David Hung, M.D., president and chief
executive officer, will be a featured speaker on two panels at the RBC Capital
Markets 2008 Healthcare Conference on Thursday, December 11, in New York:
-- "Waging A Battle Against Cancer" from 8:00-8:55 a.m. Eastern Time
-- "The Challenge of Alzheimer's Disease" from 12:00-12:55 p.m. Eastern
Time
A live audio webcast of each panel will be available on the "Events and
Presentations" page of the "Investor Relations" section of the Company's
website at http://www.medivation.com. A replay also will be available for 30
days following the live presentation.
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel small molecule drugs to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients and
their caregivers. In September 2008, Medivation entered into a global
agreement with Pfizer Inc to develop and commercialize Dimebon for the
treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company
is conducting a broad Dimebon clinical development program, including a
pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, for
patients with mild-to-moderate Alzheimer's disease. The program also includes
additional trials planned to begin next year in Alzheimer's disease, as well
as further development of Dimebon for patients with mild-to-moderate
Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in
patients with castration-resistant (also known as hormone-refractory) prostate
cancer is ongoing. For more information, please visit us at
http://www.medivation.com.
